Transderm, Inc. | Date: 2016-10-21
A therapeutic toxin dosage form for treating a disease, disorder, or condition in a subject can include a microneedle array and a therapeutically effective amount of a therapeutic toxin loaded to the microneedle array for administration to the subject. Additionally, a method of treating a disease, disorder, or condition in a subject can include administering a therapeutically effective amount of a therapeutic toxin to the subject via a microneedle array.
Transderm, Inc. | Date: 2014-01-24
The present invention is drawn to formulations for the transdermal delivery of rapamycin or other related compounds. Specifically, in one embodiment a formulation for transdermally delivering rapamycin includes an mTOR inhibitor, such as rapamycin, water, a polymer having surfactant properties, a polymer having thickening properties, a solvent for solubilizing the mTOR inhibitor, a glycol, a C_(10)-C_(20 )fatty acid; and a base.
Transderm, Inc. | Date: 2013-07-01
A method for keratin hyperproliferation disorders such as corns, calluses, or keratosis pilaris (KP) by administering to a subject experiencing the disorder a therapeutically effective amount of an RNA sequence which inhibits expression of a gene encoding for a keratin selected from the group consisting of K6a, K6b, K16, K17, and combinations thereof.
Agency: Department of Health and Human Services | Branch: | Program: SBIR | Phase: Phase I | Award Amount: 225.00K | Year: 2014
DESCRIPTION (provided by applicant): We discovered that the inducible keratins 6a and 6b, mutations in which can result in the skin and nail disorder pachyonychia congenita (PC), contain regulatory motifs in their 5'-untranslated regions that make them susceptible to mTOR inhibitors, including rapamycin. Using RNA profiling and immunohistochemistry of foot sole biopsies taken from PC lesions or adjacent unaffected skin, we found evidence to support that mTOR signaling in PC lesions is activated as indicatedby hyperphosphorylated ribosomal protein S6. Based on the preclinical data, we completed a small off- label study of orally-administered Rapamune(R) in three PC patients in which improvement of PC symptoms was observed, with dramatic reduction of painfulneurovascular structures. However, the study was prematurely terminated due to the adverse events associated with systemic oral rapamycin administration. A recent off-label study with topical rapamycin led to marked improvement of PC symptoms, includi
Transderm, Inc. | Date: 2015-06-30
The present invention provides for microneedle arrays and related systems and methods. Particularly, microneedle arrays that are configured to deliver active agents, including nucleic acids and vaccines, are provided. Additional related methods of vaccinating and minimizing the amount of vaccine necessary for effective inoculation are also provided.
Transderm, Inc. | Date: 2015-12-08
A method of treating or preventing keratin hyperproliferation skin disorders is set forth. The method includes the administration of an mTOR inhibitor to a subject afflicted with the hyperproliferation disorder. The mTOR inhibitor can be administered to the subject via any means known in the art including oral, topical, and transdermal administration.
Transderm, Inc. | Date: 2013-02-04
The present invention provides for transdermal delivery devices having microneedle arrays, as well as methods for their manufacture and use. In one embodiment, a transdermal delivery device is provided. The transdermal delivery device includes a polymer layer which has microneedles projecting from one of its surfaces. The microneedles are compositionally homogenous with the polymer base layer.
Transderm, Inc. and Samyang Biopharmaceuticals Corporation | Date: 2014-07-30
Disclosed is a transdermal preparation, comprising sequentially-stacked layers of a backing layer, a barrier layer, a drug adhesive layer and a release layer, wherein the drug adhesive layer contains a drug selected from the group consisting of fentanyl, an analogue thereof and a pharmaceutically-acceptable salt thereof, a skin permeation enhancer of the drug, and a polyacrylate adhesive, which shows a high skin permeation with a low drug dosage, equivalent to one with high drug dosage, by increasing the skin permeation rate of drug.
Transderm, Inc. | Date: 2015-12-10
Methods of treating pain and/or itch in a targeted region of a subject and compositions and dosage forms therefor are described herein. Such methods can include topically administering a therapeutically effective amount of an mTOR pathway inhibitor to the subject.
Agency: Department of Health and Human Services | Branch: National Institutes of Health | Program: SBIR | Phase: Phase I | Award Amount: 224.66K | Year: 2016
ABSTRACT The rare genetic disorder pachyonychia congenita PC results from dominant mutations in the inducible keratins K including K a K b K and K While disabling painful plantar keratoderma is commonly accepted as the primary symptom affecting patient quality of life hyperhidrosis appears to contribute to blister formation and pain Supporting the involvement of hyperhidrosis to PC pain several teams worldwide have shown that multiple intradermal injections of botulinum toxin BTX known to effectively treat hyperhidrosis substantially reduce pain and blistering in PC patients similar results were observed with the related genodermatosis epidermolysis bullosa simplex Unfortunately the number of dermal injections associated with the current treatment protocol makes this procedure costly and difficult on the patient regional nerve blocks or general anesthesia are used We propose to use TransDermandapos s proprietary Flex PAD delivery system to administer BTX to the skin in a patient friendly manner with little or no pain and with no requirement for anesthetic In Phase we aim to demonstrate that BTX can be effectively and efficiently loaded on Flex PADs and that the resulting drug product has sufficient stability to be evaluated in mouse models and for future clinical trial use The ability of the Flex PADs to delivery BTX will be evaluated in head to head studies with intradermal injection of BTX and scored for its ability to block pilocarpine induced sweating in mouse paws In Phase we refine and streamline manufacture and loading of the Flex PADs with BTX and perform IND enabling stability and toxicity studies in mice and minipig models in preparation for human studies !NARRATIVE Much progress has been made over the past two decades in identifying the underlying genes and mutations responsible for a large number of genodematoses with over disorders identified from mutations in intermediate filament genes alone Despite these discoveries few clinical treatments have emerged that modulate these molecular targets In the skin disorder pachyonychia congenita PC the causative genes for PC are expressed in sweat glands and the structure of the sweat gland is grossly altered and malformed Preliminary human studies suggest that botulinum toxin is effective in reducing hyperhidrosis and pain in PC Although injected botulinum toxin reduced PC symptoms administration is cumbersome and costly with regional nerve blocks or general anesthesia required This project seeks to exploit the ability of TransDermandapos s Flex PAD delivery platform to deliver large charged proteins such as botulinum toxin in a patient friendly i e little or no pain fashion Patient friendly delivery of botulinum toxin by Flex PADs has potential applicability to benefit not only PC patients but also other patients with hyperhidrosis and associated pain including psoriasis such as epidermolysis bullosa simplex